About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
(C) 2024 MINKABU THE INFONOID, Inc.

SymBio Pharmaceuticals Limited(4582) Financial Results

4582
TSE Growth
SymBio Pharmaceuticals Limited
205
JPY
-5
(-2.38%)
Dec 23, 3:30 pm JST
1.30
USD
Dec 23, 1:30 am EST
Result
PTS
outside of trading hours
204
Dec 23, 7:28 pm JST
Summary Chart Historical News Financial Result
Current Period Guidance
Annual
Result
Guidance History
Growth Rate
Profitability
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2020 2,987 -4,506 -4,615 -4,090 -124.1 0 Feb 4, 2021 J-GAAP
Dec, 2021 8,256 1,016 1,001 2,032 53.0 0 Feb 10, 2022 J-GAAP
Dec, 2022 10,008 1,963 1,999 1,179 30.2 0 Feb 9, 2023 J-GAAP
Dec, 2023 5,589 -811 -736 -1,962 -49.2 0 Feb 8, 2024 J-GAAP
Dec, 2024 Guidance 2,623 -3,702 -3,524 -3,628 -79.2 0 May 7, 2024 J-GAAP
YoY -53.1% -356.5% -378.8% -84.9% -60.9%
All-Time High
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 10,008 1,963 1,999 2,032 53.0
Fiscal Year Dec, 2022 Dec, 2022 Dec, 2022 Dec, 2021 Dec, 2021
Second Half
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2021 5,110 1,210 1,204 2,237 58.4 0 Feb 10, 2022 J-GAAP
Jul - Dec, 2022 5,135 591 552 71 1.8 0 Feb 9, 2023 J-GAAP
Jul - Dec, 2023 2,411 -762 -802 -1,883 -47.2 0 Feb 8, 2024 J-GAAP
Jul - Dec, 2024 Guidance 1,339 -1,983 -2,043 -2,087 -45.5 0 Aug 1, 2024 J-GAAP
YoY -44.5% -160.2% -154.7% -10.8% +3.6%
Cash Flow
Annual
Fiscal Year Operating Profit Fee Cash Flow Operating Cash Flow Investing Cash Flow Financial Cash Flow Cash & Equivalents Cash Ratio Accounting Standards
Dec, 2021 1,016 70 140 -70 -71 3,860 45.67 J-GAAP
Dec, 2022 1,963 1,567 1,614 -47 627 6,282 60.21 J-GAAP
Dec, 2023 -811 -570 -194 -376 680 6,517 79.77 J-GAAP
Actual Performance and Financial Trends
Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Sep, 2022 7,355 1,588 1,843 1,555 40.0 92.2 Nov 8, 2022 J-GAAP
Jan - Sep, 2023 4,421 -283 -156 -788 -19.9 Nov 14, 2023 J-GAAP
Jan - Sep, 2024 1,898 -2,791 -2,759 -2,845 -63.4 Oct 31, 2024 J-GAAP
YoY -57.1% -886.2% -1,668.6% -261.0% -218.9%
Quarterly Results
Result
Growth Rate
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2022 2,653 375 156 -376 -9.6 14.1 Feb 9, 2023 J-GAAP
Jan - Mar, 2023 1,544 51 48 4 0.1 3.3 Apr 27, 2023 J-GAAP
Apr - Jun, 2023 1,634 -100 18 -83 -2.1 -6.1 Aug 3, 2023 J-GAAP
Jul - Sep, 2023 1,243 -234 -222 -709 -17.9 -18.8 Nov 14, 2023 J-GAAP
Oct - Dec, 2023 1,168 -528 -580 -1,174 -29.4 -45.2 Feb 8, 2024 J-GAAP
Jan - Mar, 2024 597 -806 -727 -777 -18.0 -135.0 May 7, 2024 J-GAAP
Apr - Jun, 2024 687 -913 -754 -764 -17.2 -132.9 Aug 1, 2024 J-GAAP
Jul - Sep, 2024 614 -1,072 -1,278 -1,304 -29.1 -174.6 Oct 31, 2024 J-GAAP
YoY -50.6% -358.1% -475.7% -83.9% -62.4%
All-Time High Quarterly Results
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 2,703 863 969 1,708 44.6
Fiscal Year Dec, 2021 Jun, 2022 Jun, 2022 Dec, 2021 Dec, 2021
Key Balance Sheet Figures
Fiscal Year BPS Equity Ratio Total Asset Equity Retained Earnings Interest-Bearing Debt Ratio Announce Accounting Standards
Dec, 2021 162.26 73.7 8,452 6,226 -27,977 Feb 10, 2022 J-GAAP
Dec, 2022 204.83 77.6 10,433 8,094 -26,889 Feb 9, 2023 J-GAAP
Dec, 2023 164.32 84.8 8,170 6,932 -28,852 Feb 8, 2024 J-GAAP
Jan - Sep, 2024 80.0 6,067 4,851 -31,696 Oct 31, 2024 J-GAAP